FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileImugene Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
IMU.AX
Imugene Limited Stock AnalysisComprehensive stock analysis for Imugene Limited (IMU.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisIMU.AX
IMU.AX
Imugene Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Discussion
IMU.AX
  1. Home
  2. Stocks
  3. Imugene Limited

Imugene Limited

🇦🇺IMU.AX•ASX

Imugene Limited

🇦🇺IMU.AX•ASX

Your view on IMU.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Imugene Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Leslie Chong
Headquarters
4-6 Bligh Street, Sydney, NSW, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Leslie Chong
Headquarters
4-6 Bligh Street, Sydney, NSW, AU
Description

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study.

The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer.

Imugene Limited is headquartered in Sydney, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Imugene Limited. Starting points for Imugene Limited: EPS -AUD 0.30, beta 2.14 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Imugene Limited. Imugene Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Imugene Limited. Trailing twelve-month EPS for Imugene Limited stands at -AUD 0.30. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 20, 2026
More →

Earnings per share estimates

Per shareThis quarterJun 2015Next quarterJun 2016This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 0.00AUD 0.00−AUD 0.06−AUD 0.04
Lowest estimateAUD 0.00AUD 0.00−AUD 0.08−AUD 0.07
Highest estimateAUD 0.00AUD 0.00−AUD 0.03−AUD 0.03
Number of analysts2223
A year ago——−AUD 0.321—
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterJun 2015Next quarterJun 2016This yearYear to Jun 2027Next yearYear to Jun 2028
Average estimateAUD 304499.00AUD 811999.00AUD 1.67MAUD 16.80M
Lowest estimateAUD 291000.00AUD 776000.00AUD 1.67MAUD 16.80M
Highest estimateAUD 306000.00AUD 816000.00AUD 1.67MAUD 16.80M
Number of analysts2212
A year ago——AUD 0.00—
Growth vs a year ago————

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Imugene Limited. Imugene Limited has reported as a listed company since 1993. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold IMU.AX20 companies
Compare IMU.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ACW.AXActinogen Medical LimitedHealthcareBiotechnology—
ALA.AXArovella Therapeutics LimitedHealthcareBiotechnology—
ATH.AXAlterity Therapeutics LimitedHealthcareBiotechnology—
BIO.AXBiome Australia LimitedHealthcareMedical - Pharmaceuticals—
EZZ.AXEZZ Life Science Holdings LimitedHealthcareBiotechnology—
ILA.AXIsland Pharmaceuticals LimitedHealthcareBiotechnology—
PCK.AXPainChek LimitedHealthcareMedical - Healthcare Information Services—
RAD.AXRadiopharm Theranostics LimitedHealthcareBiotechnology—
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
ONCO.NEOnco-Innovations LimitedHealthcareNEO—
ONCSQOncoSec Medical IncorporatedHealthcareOTC$596
ONCYOncolytics Biotech Inc.HealthcareNASDAQ$44.2M
ONPHOncology Pharma Inc.HealthcareOTC$109,553
ONTTFOxford Nanopore Technologies plcHealthcareOTC$1.8B
OPORFhVIVO plcHealthcareOTC$59.2M
ORGSOrgenesis Inc.HealthcareOTC$3.0M
ORICORIC Pharmaceuticals, Inc.HealthcareNASDAQ$795.1M
ORKAOruka Therapeutics, Inc.HealthcareNASDAQ$6.5B
ORMPOramed Pharmaceuticals Inc.HealthcareNASDAQ$169.2M
ORPOFOSE Immunotherapeutics S.A.HealthcareOTC$260.3M
ORYZFOryzon Genomics S.A.HealthcareOTC$283.9M
Open Comparable Analysis
Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Imugene Limited.

IMU.AX AnalysisWeak
Past
1
Growth
1
Health
3
Profit
1
Value
1